Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity
Communications Biology · 03.05.2024 · 7 (1)
DOI: 10.1038/s42003-024-05922-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communications Biology, online erschienen am 03.05.2024. Verfasst von Thai Hien Tu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Départment of Medicine, Universite de Montreal, Montreal, QC, H3T 1J4, Canada. Hauptthemen laut MEDLINE: COVID-19, Severity of Illness Index, SARS-CoV-2, Hepatocyte Nuclear Factor 1-alpha. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada).
Abstract (Originalsprache)
COVID-19, caused by SARS-CoV-2, can lead to a severe inflammatory disease characterized by significant lymphopenia. However, the underlying cause for the depletion of T-cells in COVID-19 patients remains incompletely understood. In this study, we assessed the presence of different T-cell subsets in the progression of COVID-19 from mild to severe disease, with a focus on TCF1 expressing progenitor T-cells that are needed to replenish peripheral T-cells during infection. Our results showed a preferential decline in TCF1+ progenitor CD4 and CD8+ T-cells with disease severity. This decline was seen in various TCF1+ subsets including naive, memory and effector-memory cells, and surprisingly, was accompanied by a loss in cell division as seen by a marked decline in Ki67 expression. In addition, TCF1+ T-cells showed a reduction in pro-survival regulator, BcL2, and the appearance of a new population of TCF1 negative caspase-3 expressing cells in peripheral blood from patients with severe disease. The decline in TCF1+ T-cells was also seen in a subgroup of severe patients with vitamin D deficiency. Lastly, we found that sera from severe patients inhibited TCF1 transcription ex vivo which was attenuated by a blocking antibody against the cytokine, interleukin-12 (IL12). Collectively, our findings underscore the potential significance of TCF1+ progenitor T-cells in accounting for the loss of immunity in severe COVID-19 and outline an array of markers that could be used to identify disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Départment of Medicine, Universite de Montreal, Montreal, QC, H3T 1J4, Canada.
- Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC, H3T 1J4, Canada.
- Division of Immunology-Oncology, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, H1T 2M4, Canada.
- Division of Experimental Medicine, McGill University, Montreal, QC, H3A 0G4, Canada.
- Department of Medicine, Research Institute of the McGill University Health Center, Montreal, H3A 0G4, Canada.
- Division of Medical Biochemistry, McGill University Health Centre, Montréal, QC, Canada.
ORCID-Profile: Nicholas Rozza, Christopher E Rudd
Förderung
- Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)
Zitieren
APA
Tu, T. H., Grunbaum, A., Santinon, F., Kazanova, A., Rozza, N., Kremer, R., Mihalcioiu, C., & Rudd, C. E. (2024). Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity. Communications Biology, 7(1). https://doi.org/10.1038/s42003-024-05922-2
Vancouver
Tu TH, Grunbaum A, Santinon F, Kazanova A, Rozza N, Kremer R, et al. Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity. Communications Biology. 2024;7(1). doi:10.1038/s42003-024-05922-2
BibTeX
@article{Tu2024,
author = {Tu, Thai Hien and Grunbaum, Ami and Santinon, François and Kazanova, Alexandra and Rozza, Nicholas and Kremer, Richard and Mihalcioiu, Catalin and Rudd, Christopher E},
title = {Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity},
journal = {Communications Biology},
year = {2024},
volume = {7},
number = {1},
doi = {10.1038/s42003-024-05922-2}
}
EUVIMED